Key research priorities include refining epidemiological estimates, standardizing biomarker cut-offs, elucidating dynamic interactions between alcohol and CMRFs, validating non-invasive prognostic tools, and evaluating therapies that target both metabolic and alcohol-related injury.
Chronic liver disease is a leading cause of global morbidity and mortality, with an evolving etiologic landscape driven by rising metabolic dysfunction and persistent alcohol use. The introduction of metabolic and alcohol-associated liver disease (MetALD) recognizes the coexistence of these exposures as dual drivers of...
Gurmehr Brar, Brian P. Lee· Hepatology Communications· 0 citations
Background: Alcohol-associated liver disease (ALD) is a leading cause of advanced liver disease and liver transplantation worldwide. Cardiometabolic risk factors (CMRFs) may worsen ALD prognosis. While recent nomenclature acknowledges the impact of CMRFs in steatotic liver disease with low-to-moderate alcohol use, indi...
Dhiraj K Peddu, Vitchapong Prasitsumrit, Matthew Kubina et al.· Hepatology Communications· 0 citations
The association between alcohol intake and MALOs remained stable over time despite increasing metabolic burden, suggesting that increasing metabolic burden has not modified the association between alcohol intake and liver outcomes at the population level.
Eneli Katunin, V. Männistö, F. Åberg· Liver international (Print)· 0 citations
Metabolic dysfunction-associated steatotic liver disease with increased alcohol consumption (MetALD) is a newly defined category within the spectrum of steatotic liver disease. It captures patients who have both cardiometabolic risk factors and alcohol intake above the thresholds accepted for metabolic dysfunction-asso...
The largest-to-date genome-wide association study of liver fat in 79,642 people with magnetic resonance imaging and developed a polygenic score with liver fat-lowering alleles across 55 genomic loci demonstrate the profound etiologic impact of liver fat in MASH and provide compelling evidence for liver fat reductions a...
N. Verweij, G. Hindy, Q. Nguyen et al.· medRxiv· 0 citations
Accurate classification and risk stratification across metabolic dysfunction-associated steatotic liver disease (MASLD), MetALD, and alcohol-associated liver disease (ALD) depend critically on the assessment of alcohol exposure. However, current clinical practice relies largely on self-reported alcohol intake, which ma...
Hyo Young Lee, E. Yoon, D. Jun· Clinical and Molecular Hepat...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.